INJECTABLE
ALEVATRIX
ALEVATRIX is a preclinical investigational drug we're developing to provide postoperative pain relief for 72 hours, minimizing the need for opioid analgesics. It utilizes a patented drug delivery technology to provide a sustained therapeutic dosage of local anesthetic to the surgical site.
​
At Rebel, we believe no patient should have to choose between pain relief and the risk of opioid dependence. Using readily available and stable materials, we're designing ALEVATRIX to have low manufacturing and storage costs, enabling us to bring a non-opioid solution to more patients.
​
WHY ALEVATRIX?
NON-OPIOID
ALEVATRIX directly targets the nerves at the surgical site to provide pain relief without the systemic side effects experienced with opioids.
72-HOUR RELIEF
ALEVATRIX provides 72 hours of pain relief to patients
REDUCE COST
ALEVATRIX has the potential to reduce the cost of surgery my minimizing opioid-related adverse events and shortening hospital stays.
BIOCOMPATIBLE
ALEVATRIX is composed of FDA-approved materials and is proven safe for humans
INJECTABLE
ALEVATRIX can be infiltrated in the surgical wound for field block or injected near a peripheral nerve for a regional block
WHY ALEVADERM?
NON-OPIOID
ALEVADERM directly targets the exposed dermal nerve endings to provide pain relief without requiring systemic opioids.
UP TO 7 DAY DURATION
ALEVADERM's release profile can be tuned to meet various wound indications
MOIST WOUND HEALING
ALEVADERM maintains
a moist wound microenvironment to promote natural wound healing
BIOCOMPATIBLE
ALEVADERM is composed of materials that degrade into normal human metabolites
MINIMIZES DRESSING CHANGE
ALEVADERM remains
on the wound until reepithelialization, reducing the pain and wound disruption that occurs with dressing changes
DRESSING
ALEVADERM
ALEVADERM is a combination wound dressing in preclinical development that can deliver local anesthetics for up to 7 days. This dressing combines the ideal attributes of moist wound healing and prolonged analgesia to address the most important concerns of patients with painful wounds.
​
Initially targeted for painful partial-thickness wounds such as abrasions, second-degree burns and split-thickness skin graft donor sites, ALEVADERM functions as a temporary epidermal replacement controlling wound fluid and moisture to promote optimal wound healing.
Compared to existing products, this combination dressing promises greater pain control and improved clinical efficiency for the treatment of severely painful wounds.
​
Human-centered wound care.